New hope for brain tumors: drug targets genetic weakness

NCT ID NCT05588141

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called zotiraciclib in people with a certain type of brain tumor (glioma) that has come back after treatment. The tumor must have a specific gene mutation (IDH1 or IDH2). Participants take the drug by mouth in cycles. The goal is to see if the drug can slow tumor growth and to find the best dose with the fewest side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

zotiraciclib

What this could lead to

If it works, this could offer a new treatment option to slow or stop the growth of recurrent IDH-mutant gliomas.

What could go wrong

This is an early-phase trial with a small number of participants. The drug may not be effective or could cause significant side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm cancer glioma neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-••••